Is AbbVie the Best Dividend Stock in Healthcare?
AbbVie (NYSE: ABBV) is making headway toward diversifying itself away from its best-selling drug, Humira, but Humira still accounts for most of its sales and that makes buying AbbVie, because of its enticing dividend yield, a bit risky.
In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss how AbbVie is trying to protect itself from Humira competition in the future and if its efforts are enough to warrant buying its shares.
A full transcript follows the video.
Source: Fool.com
Gilead Sciences Inc Aktie
71,02 €
0,07 %
Eine klare Neigung zu Buy-Einschätzungen bei Gilead Sciences Inc, ohne Sell-Einschätzungen.
Ein Kursziel von 85 € für Gilead Sciences Inc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 71.02 €.
